Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1.

Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1.
复制标题

DOI:
10.1186/s12885-023-11613-8
复制
发表时间:
2023-12-06
期刊:
影响因子:
3.8
通讯作者:
Li, Jian
Li, Jian
中科院分区:
医学2区
文献类型:
--
作者:
Zhao, Jiali;Lin, En;Bai, Zirui;Jia, Yingbin;Wang, Bo;Dai, Yihua;Zhuo, Wenfeng;Zeng, Guifang;Liu, Xialei;Cai, Chaonong;Li, Peiping;Zou, Baojia;Li, Jian

文献摘要

参考文献

相似文献

由于肝细胞癌(HCC)的高耐药性,索拉非尼治疗晚期HCC的疗效有限。癌相关成纤维细胞(CAFs)在诱导化疗耐药中起着重要的调节作用。本研究旨在阐明肝癌中CAF介导的索拉非尼耐药性的机制。免疫组化和免疫荧光显示肝癌组织中CAFs的活化增强。分别从HCC的癌组织和癌旁组织中分离CAFs和癌旁正常成纤维细胞(NFs)。细胞克隆测定、ELISA和流式细胞术用于检测CAF是否通过CXCL 12诱导HCC细胞中的索拉非尼抗性。Western blotting和qPCR显示CXCL 12通过上调FOLR 1诱导HCC细胞中的索拉非尼耐药。我们通过查询GEO数据库中人HCC标本的基因表达数据,研究FOLR 1是否是调节HCC细胞索拉非尼耐药的CAF的靶分子。高水平的激活CAFs存在于肝癌组织中,而不是在癌旁组织。CAFs降低了HCC细胞对索拉非尼的敏感性。我们发现CAF分泌CXCL 12,其上调HCC细胞中的FOLR 1以诱导索拉非尼耐药。CAF通过CXCL 12/FOLR 1诱导肝癌细胞对索拉非尼耐药。在线版本包含补充材料,可通过10.1186/s12885-023-11613-8获得。
Due to the high drug resistance of hepatocellular carcinoma (HCC), sorafenib has limited efficacy in the treatment of advanced HCC. Cancer-associated fibroblasts (CAFs) play an important regulatory role in the induction of chemoresistance. This study aimed to clarify the mechanism underlying CAF-mediated resistance to sorafenib in HCC. Immunohistochemistry and immunofluorescence showed that the activation of CAFs was enhanced in HCC tissues. CAFs and paracancerous normal fibroblasts (NFs) were isolated from the cancer and paracancerous tissues of HCC, respectively. Cell cloning assays, ELISAs, and flow cytometry were used to detect whether CAFs induced sorafenib resistance in HCC cells via CXCL12. Western blotting and qPCR showed that CXCL12 induces sorafenib resistance in HCC cells by upregulating FOLR1. We investigated whether FOLR1 was the target molecule of CAFs regulating sorafenib resistance in HCC cells by querying gene expression data for human HCC specimens from the GEO database. High levels of activated CAFs were present in HCC tissues but not in paracancerous tissues. CAFs decreased the sensitivity of HCC cells to sorafenib. We found that CAFs secrete CXCL12, which upregulates FOLR1 in HCC cells to induce sorafenib resistance. CAFs induce sorafenib resistance in HCC cells through CXCL12/FOLR1. The online version contains supplementary material available at 10.1186/s12885-023-11613-8.
DOI: 10.3390/ijms22147371
发表时间: 2021-07-09
影响因子: 5.6
作者:
Khare T;Bissonnette M;Khare S
通讯作者: Khare S
DOI: 10.1158/1541-7786.mcr-12-0307
发表时间: 2012-11
期刊: Molecular cancer research : MCR
影响因子: --
作者:
Karagiannis GS;Poutahidis T;Erdman SE;Kirsch R;Riddell RH;Diamandis EP
通讯作者: Diamandis EP
CXCL12对面神经损伤具有治疗价值,通过PI3K-AKT-mTOR信号通路促进雪旺细胞自噬和迁移
DOI: 10.1016/j.ijbiomac.2018.10.212
发表时间: 2019-03-01
影响因子: 8.2
作者:
Gao, Dekun;Tang, Tianchi;Li, Shiting
通讯作者: Li, Shiting
DOI: 10.1084/jem.20131195
发表时间: 2013-12-16
期刊: The Journal of experimental medicine
影响因子: --
作者:
Lotti F;Jarrar AM;Pai RK;Hitomi M;Lathia J;Mace A;Gantt GA Jr;Sukhdeo K;DeVecchio J;Vasanji A;Leahy P;Hjelmeland AB;Kalady MF;Rich JN
通讯作者: Rich JN
与癌症相关的成纤维细胞衍生的分泌磷蛋白1有助于肝细胞癌对索拉非尼和伦瓦替尼的抗性。
DOI: 10.1002/cac2.12414
发表时间: 2023-04
期刊: Cancer communications (London, England)
影响因子: --
作者:
通讯作者: --